These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10781756)

  • 1. Effect of coronary angiography on use of lipid-lowering agents in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. For the WISE Investigators.
    Bittner V; Olson M; Kelsey SF; Rogers WJ; Bairey Merz CN; Armstrong K; Reis SE; Boyette A; Sopko G
    Am J Cardiol; 2000 May; 85(9):1083-8. PubMed ID: 10781756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
    Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
    JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease.
    Harnick DJ; Cohen JL; Schechter CB; Fuster V; Smith DA
    Am J Cardiol; 1998 Jun; 81(12):1416-20. PubMed ID: 9645890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative.
    LaBresh KA; Owen P; Alteri C; Reilly S; Albright PS; Hordes AR; Shaftel PA; Noonan TE; Stoukides CA; Kaul AF
    Am J Cardiol; 2000 Feb; 85(3A):23A-29A. PubMed ID: 10695704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns.
    Ruof J; Klein G; März W; Wollschläger H; Neiss A; Wehling M
    Prev Med; 2002 Jul; 35(1):48-53. PubMed ID: 12079440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials.
    White CW
    Am J Med; 1998 Jul; 105(1A):63S-68S. PubMed ID: 9707270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study in primary care in patients without vascular disease comparing levels of coronary risk factors in those recommended for lipid-lowering drugs based on either absolute risk or absolute risk reduction.
    Ramachandran S; Croft P; Neary RH
    Prev Cardiol; 2003; 6(1):17-21. PubMed ID: 12624557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering in the cardiac rehabilitation setting.
    Ades PA; Savage PD; Poehlman ET; Brochu M; Fragnoli-Munn K; Carhart RL
    J Cardiopulm Rehabil; 1999; 19(4):255-60. PubMed ID: 10453433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting.
    Lacy CR; Suh DC; Barone JA; Bueno M; Moylan D; Swartz C; Kudipudi RV; Kostis JB
    Arch Intern Med; 2002 Feb; 162(4):468-73. PubMed ID: 11863482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicians' attitudes toward preventive therapy for coronary artery disease: is there a gender bias?
    Abuful A; Gidron Y; Henkin Y
    Clin Cardiol; 2005 Aug; 28(8):389-93. PubMed ID: 16144216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators.
    Miller M; Byington R; Hunninghake D; Pitt B; Furberg CD
    Arch Intern Med; 2000 Feb; 160(3):343-7. PubMed ID: 10668836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of lipid lowering in coronary artery disease.
    Goldberg AC
    Curr Opin Cardiol; 1997 Sep; 12(5):488-93. PubMed ID: 9352177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of lipid-lowering drugs in elderly persons with increased serum low-density lipoprotein cholesterol associated with coronary artery disease, symptomatic peripheral arterial disease, prior stroke, or diabetes mellitus before and after an educational program on dyslipidemia treatment.
    Ghosh S; Aronow WS
    J Gerontol A Biol Sci Med Sci; 2003 May; 58(5):M432-5. PubMed ID: 12730252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Under treatment with lipid-lowering drugs of high-risk coronary heart disease patients of the GENICA study.
    Cesari M; Maiolino G; Colonna S; Zanchetta M; Pedon L; Maiolino P; Pessina AC; Rossi GP
    J Cardiovasc Pharmacol; 2003 Oct; 42(4):484-90. PubMed ID: 14508233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
    Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
    J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attainment of low-density lipoprotein cholesterol goals in coronary artery disease.
    Kauffman AB; Olson KL; Youngblood ML; Zadvorny EB; Delate T; Merenich JA;
    J Clin Lipidol; 2010; 4(3):173-80. PubMed ID: 21122649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipid lowering therapy for primary prevention of coronary heart disease--pro lipid lowering therapy].
    Steinmetz A; Noll B; Maisch B; Schäfer JR
    Z Kardiol; 1998; 87 Suppl 2():205-9. PubMed ID: 9827484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.